|Volume 6 Issue 148 Published - 14:00 UTC 08:00 EST 27-May-2004 Next Update - 14:00 UTC 08:00 EST 28-May-2004||Editor: Susan K. Boyer, RN
Š Vidyya., Inc.
All rights reserved.
Data demonstrate that Benicar(R) and Benicar HCT (TM) achieve JNC 7 blood pressure goals
New data from two different clinical studies demonstrated that patients with hypertension can achieve more aggressive blood pressure goal rates using antihypertensive therapies BenicarŽ (olmesartan medoxomil) or Benicar HCTTM (olmesartan medoxomil/hydrochlorothiazide).
The first, recently published in the Journal of Clinical Hypertension, is a study that demonstrated that nearly seven out of ten or 69.3 percent of patients treated with Benicar, or if needed with Benicar HCT, were able to reach a more aggressive blood pressure goal of less than or equal to 130/85 mm Hg.
The second, presented at the annual meeting of the American Society of Hypertension, was a secondary analysis of data from a previously published clinical study. Data from this analysis showed that at the usual recommended starting doses, approximately twice as many patients treated with Benicar achieved goal blood pressure of less than 140/90 mm Hg* compared to CozaarŽ (losartan potassium) and DiovanŽ (valsartan), the two most commonly prescribed angiotensin II receptor blockers (ARBs).
In 2003, the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure issued its seventh report (JNC 7) outlining its more aggressive guidelines for hypertension prevention and management. These guidelines stress the importance of helping patients achieve goal blood pressure of less than 140/90 mm Hg, or less than 130/80 mm Hg for patients with diabetes or chronic kidney disease. These goals are important because the risk of cardiovascular disease (CVD) doubles with each increment of 20/10 mm Hg beginning at 115/75 mm Hg. JNC 7 guidelines also recommend a step-wise treatment approach, in which the dose of the first antihypertensive agent is titrated upwards and then additional agents added, as necessary, to achieve blood pressure goals.
"Most head-to-head trials of hypertension therapies compare the benefits of each agent in terms of how effective it is in decreasing millimeters of mercury, the measurement units of systolic and diastolic blood pressure," states Suzanne Oparil, MD, Professor of Medicine, and Director, Vascular Biology and Hypertension, University of Alabama at Birmingham. "However, in light of the JNC 7 guidelines, which stress the importance of achieving goal blood pressure rates, physicians also need to know how effective a therapy is in helping a patient reach goal." **
Hypertension, also known as high blood pressure, affects approximately 50 million people in the United States and approximately one billion worldwide. Called the "silent killer" because it often has no specific symptoms, hypertension increases the risk of cardiovascular and related diseases such as stroke, heart attack, heart failure and kidney disease.4
Benicar and Benicar HCT in Treating to Goal
The study also evaluated the effectiveness of the approach in reaching individual systolic and diastolic goals. At week eight, nearly two out of three (65.9 percent) patients reached goal diastolic blood pressure of less than or equal to 85 mm Hg on Benicar monotherapy alone (20 and 40 mg). At week 16, nearly three out of four (72.6 percent) achieved goal systolic blood pressure of less than or equal to 130 mm Hg, and nearly nine out of ten (87.2 percent) achieved goal diastolic blood pressure of less than or equal to 85 mm Hg using Benicar or Benicar HCT.
Benicar Compared to Other ARBs in Reaching Goal Blood Pressure
The data demonstrated that twice as many patients who received Benicar reached goal blood pressure of less than 140/90 mm Hg (32.4% of patients) compared to patients who received Cozaar (16.1% of patients) and Diovan (14.5% of patients), and approximately 25 percent more compared to patients who took Avapro (25.9% of patients). While less than 140/90 is the JNC 7 blood pressure goal for uncomplicated patients with hypertension, further analysis was completed at the more aggressive blood pressure goal of less than 130/85 and found that almost three times as many patients were able to reach this goal on Benicar (12.5% of patients) compared to Cozaar (4.4% of patients) and Diovan (3.1% of patients), and about one-third more versus Avapro (9.4% of patients).
About Benicar and Benicar HCT